【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》正式发布，推动 iBCI 临床转化科学、安全、有序发展； 2、民政部印发《关于进一步推进民政科技创新的指导意见》，《意见》要求广泛应用人形机器人、脑机接口、人 工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和社会参与促进、安全风险监 测和紧急救援、老年宜居 仅需3分钟就能迅速打开血脑屏障，与血脑屏障未开放的脑组织相比，药物浓度可以平均提高8倍，并且在治疗后6 小时关闭血脑屏障，疗效和安全性均优于国际相关报道； 7、Ybrain招募三星电子和VUNO前高管，推广基于tDCS和脑电图技术的非口服抗抑郁药、打造AI心理健康生态系 统； 8、韩国数字医疗企业Neofect宣布与韩德联合财团合作，共同推进脑机接口商业化，项目将耗时36个月（2025.9- 2028.8）研发基于脑神经控制的脑卒中患者上肢辅助与康复机器人系统。 【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》 ...

Group 1 - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.29% and the ChiNext Index falling by 0.7% [1] - The Medical Equipment ETF (159873) had a trading volume exceeding 22 million yuan and a turnover rate of 9.62%, leading among its peers [1] - As of January 16, the Medical Equipment ETF experienced a net inflow of over 10 million yuan, with a total scale of 232 million yuan, reflecting a year-to-date growth of 109% [1] Group 2 - Neuralink's brain-machine interface can undergo OTA upgrades, similar to Tesla's remote updates, enhancing its speed, precision, and reliability without the need for surgery [2] - The medical device sector is expected to see long-term investment opportunities driven by innovation, international expansion, and mergers and acquisitions, with a focus on brain-machine interfaces and AI medical technologies [2] - The commercialization of brain-machine interfaces is progressing steadily, supported by favorable policies and the anticipated mass production of Neuralink, leading to significant market growth [3]

Core Viewpoint - The article discusses the return of Chen Tianqiao, a prominent figure in the Chinese internet industry, who is now focusing on brain-computer interface (BCI) technology and artificial intelligence (AI) research, marking a significant shift in his career and investment strategy [4][15]. Group 1: Chen Tianqiao's Return and Investments - Chen Tianqiao announced a $1 billion investment in computing power to support global AI research, emphasizing his commitment to advancing scientific discovery through AI [4][15]. - He co-founded "Gestalt," the first domestic ultrasound brain-computer interface company in China, which aims to develop non-invasive BCI technology [8][9]. - Chen's approach contrasts with Elon Musk's invasive BCI strategy, focusing instead on a non-invasive method that poses fewer ethical and safety concerns [9][19]. Group 2: AI and Brain Science Integration - Chen Tianqiao's new company "Tanka" is defined as a communication platform integrating AI with long-term memory capabilities, aiming to redefine organizational management in the AI era [9][10]. - He believes that AI should execute tasks while humans take responsibility for outcomes, highlighting a shift in the role of leadership in organizations [9][11]. - The integration of brain science and AI is seen as a potential pathway to understanding human cognition and emotional regulation, creating new opportunities for innovation [20]. Group 3: Historical Context and Personal Journey - Chen's interest in brain science began after experiencing panic attacks during his peak career, prompting him to explore the workings of the human brain [12][13]. - Over the past decade, he has invested in brain science research, establishing the Tianqiao Brain Science Research Institute (TCCI) with a $1 billion donation, focusing on understanding and treating brain diseases [14][15]. - His return to the public eye is characterized by a long-term vision, aiming to build a comprehensive chain from basic research to commercial application in the fields of brain science and AI [19][20].

Core Viewpoint - The article discusses the return of Chen Tianqiao, a prominent figure in the Chinese internet industry, who is now focusing on brain-computer interface (BCI) technology and artificial intelligence (AI) through his new ventures, Gestalt and Tanka, emphasizing a long-term vision in these fields [5][6][30]. Group 1: Chen Tianqiao's Return and Investments - Chen Tianqiao announced a $1 billion investment in computational power to support global AI-driven scientific research during a conference in San Francisco [5][23]. - His new company, Gestalt, focuses on non-invasive ultrasound brain-computer interfaces, contrasting with Elon Musk's invasive approach [11][12]. - Tanka, another venture, aims to create a communication platform that integrates AI with human decision-making, redefining organizational management in the AI era [15][16]. Group 2: Brain-Computer Interface Technology - The article highlights the contrasting approaches to BCI technology, with Musk's Neuralink pursuing invasive methods and Gestalt opting for a non-invasive strategy [11][12]. - Gestalt's approach is described as more complex and challenging, aiming for a comprehensive understanding of brain functions without the risks associated with surgical procedures [12][30]. - The potential for Gestalt and Tanka to collaborate could lead to significant advancements in understanding human cognition and emotional regulation [34]. Group 3: Long-term Vision and Challenges - Chen Tianqiao's strategy is characterized by a commitment to long-term research and development in brain science and AI, moving away from traditional business models [30][31]. - The challenges of clinical translation in BCI technology are noted, with timelines often extending over a decade and facing strict ethical and regulatory scrutiny [31][33]. - The article suggests that the intersection of brain science and AI could create new opportunities for innovation and understanding of human behavior [34].

Core Insights - Chen Tianqiao, the founder of Shengda Group and a prominent figure in the internet era, has made a significant return to the public eye by announcing a $1 billion investment in AI-driven scientific research, emphasizing the role of AI in driving scientific discovery [1][11] - The establishment of "Gestalt," a non-invasive ultrasound brain-computer interface company, marks a strategic shift in the approach to brain-computer interfaces, contrasting with Elon Musk's invasive methods [5][6] - Chen's new AI-native company, Tanka, aims to redefine organizational management in the AI era, proposing a model where AI executes tasks while humans take responsibility for outcomes [7][19] Investment and Research Initiatives - Chen Tianqiao announced a $1 billion investment to support global scientists in innovative AI research during a conference attended by leading scholars and industry leaders [1][11] - The TCCI (Tianqiao Brain Science Research Institute) has funded research that has been published in top journals, focusing on key areas such as serotonin mechanisms and neural circuits [10] Technological Approaches - "Gestalt" focuses on a non-invasive approach to brain-computer interfaces, utilizing external ultrasound to stimulate and regulate the brain, aiming for safer and broader brain coverage [5][6] - In contrast, Neuralink's invasive method involves implanting electrodes directly into the brain, which presents high risks and ethical challenges [4][6] Strategic Vision - Chen Tianqiao's strategy diverges from traditional business models by aiming for a comprehensive integration of brain science and AI, rather than merely enhancing existing business operations with AI [17][18] - The dual focus on brain science and AI is intended to create a new ecosystem that enhances understanding of human cognition and emotional regulation [18][19] Historical Context - Chen's shift towards brain science was influenced by personal experiences with panic attacks, prompting a deep exploration of the human brain and its functions [9][10] - His previous success in the internet industry contrasts sharply with his current focus on foundational research and long-term applications in brain science [13][17]

Core Viewpoint - Neuralink is making significant advancements in brain-computer interface (BCI) technology, aiming to enhance the quality of life for patients with paralysis and other neurological conditions through innovative surgical techniques and devices [1][4]. Group 1: Technological Advancements - The speed of the new generation surgical robot for implanting single electrode wires has improved from 17 seconds to 1.5 seconds, making it adaptable for 99% of the global population [2]. - Over a dozen subjects are currently using the device for 8 hours daily, with more than 10,000 patients waiting for treatment [2]. - The new surgical robot has increased the speed of inserting single electrode wires by several times compared to existing robots [2]. - Neuralink is developing a new type of implant needle capable of penetrating over 50mm into the brain's surface to access a richer array of neurons [2][12]. - The manufacturing cost of the needle holder has been reduced by 95% [2]. Group 2: BCI Technology and Applications - BCI technology translates neural signals into output commands, enabling control of external devices, with initial goals focused on improving the lives of millions of paralyzed patients [4]. - The first product, "Telepathy," allows individuals with spinal cord injuries or ALS to control computers and mobile devices through thought [15]. - A subject was able to play the game "Civilization VI" for 9 hours after receiving the BCI implant, showcasing the potential for everyday applications [15]. Group 3: Future Prospects - Neuralink has made continuous technological progress since its establishment in 2016, with the first human brain chip implantation scheduled for 2024 [12]. - The company aims to make surgeries as routine as LASIK eye surgery, potentially completing procedures within an hour and even while patients are awake [6]. - The long-term vision includes achieving a high-density device with thousands of channels to record more neurons and gather more information [12].

Investment Rating - The report maintains a "Positive" investment rating for the industry [5]. Core Insights - Neuralink, a leading brain-computer interface company, showcased significant advancements in its technology, indicating a potential acceleration in the commercialization of brain-computer interfaces [2][10]. - The report suggests focusing on three main investment themes: 1) domestic mapping of the advanced overseas invasive brain-computer interface supply chain; 2) product deployment of non-invasive brain-computer interfaces in consumer scenarios; 3) downstream application targets related to brain-computer interfaces [10]. Summary by Sections Event Description - On June 27, Neuralink released a one-hour video demonstrating its latest research achievements and product development directions [3]. Event Commentary - The report highlights the impressive progress of Neuralink's brain-computer interface technology, which has significantly improved the quality of life for its seven trial participants, including patients with spinal cord injuries and ALS [10]. - Future plans include the development of a "full brain interface" with milestones set for 2025 to 2027, aiming to decode conscious speech and restore vision [10]. Product Overview - Neuralink currently has three products targeting different scenarios: 1) "Telepathy" for patients with motor disabilities; 2) "Blindsight" for visually impaired individuals; 3) "Deep" for neurological disorders [10].

Core Viewpoint - Neuralink is advancing brain-machine interface technology, showcasing significant progress in clinical applications and setting ambitious future goals for enhancing human capabilities through direct brain interaction with machines [1][5][10]. Group 1: Neuralink's Current Progress - Neuralink has conducted trials with 7 participants, including 4 with spinal cord injuries and 3 with ALS, who use the device for an average of 50 hours per week, with peaks over 100 hours [1][6]. - Participants can control video games and mechanical arms using brain signals, demonstrating the practical application of the technology [4][5]. Group 2: Product Lines and Future Plans - Neuralink has developed three main product lines: 1. Telepathy: Aimed at motor-impaired patients, enabling control of electronic devices and robotic arms [5]. 2. Blindsight: Focused on visual reconstruction, aiming for black-and-white contour perception by 2026 [5][8]. 3. Deep: Targeting neurological disorders like Parkinson's and depression, with animal trials underway [5]. - The ultimate goal is to achieve a full brain interface, allowing for deep integration between biological brains and machines, potentially enabling direct thought control of robots [5][8]. Group 3: Market Potential and Industry Trends - The global brain-machine interface market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate of 17.35% [10]. - Various countries are intensifying their strategic investments in brain-machine interface technology, with China prioritizing this sector in its development plans [10]. - The industry is seeing advancements across invasive, semi-invasive, and non-invasive technologies, with non-invasive products leading in commercialization [10][11]. Group 4: Related Companies - Key players in the domestic industry include hardware manufacturers like Hanwei Technology and Jiake Intelligent, as well as application developers such as Zhongke Information and Keda Xunfei [11].